+4,437.1%
SNDK vs GSK
+42.5%
+4,394.6%
-56.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.5% | 0.0% | -3.5% | -3.5% |
| 7D | -6.1% | -3.5% | -2.6% | -6.1% |
| 30D | +21.5% | -3.4% | +25.0% | +21.5% |
| 3M | -13.2% | -8.1% | -5.1% | -13.0% |
| 6M | +149.2% | -11.1% | +160.3% | +153.6% |
| YTD | +588.1% | +0.7% | +587.3% | +556.1% |
| 1Y | +1,837.5% | +20.1% | +1,817.4% | +1,569.4% |
| All | +4,437.1% | +42.5% | +4,394.6% | +3,381.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling